Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

50 results about "Copy Number Alteration" patented technology

Markers of DNA copy number alteration for improved prognostication in prostate cancer

The invention describes DNA copy number alterations (CNAs), identifiable by technologies such as array-based comparative genomic hybridization (array CGH) or fluorescence in situ hybridization (FISH), that define distinct genetic subtypes of prostate cancer, and are useful for improved prognostication and treatment stratification for patients with prostate cancer.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Copy number alterations that predict metastatic capability of human breast cancer

Disclosed in this specification is a method of defining chromosome regions of prognostic value by summarizing the significance of all SNPs (single nucleotide polymorphism) in a predetermined section of a chromosome to define chromosome regions of prognostic value. Based on the SNPs in specified genes, a more accurate prognosis for breast cancer may be provided.
Owner:VERIDEX LCC

Probe assembly, gene capturing chip, kit and application thereof

The invention provides a probe assembly, a gene capturing chip, a kit and application. The assembly at least comprises a probe specifically combined to a target gene under the strict conditions. A special capturing probe is designed for a targeted chemotherapy medicine related gene on the basis of the DNA next generation sequencing method, a plurality of target gene segments are obtained at a time through a small number of samples, high-depth sequencing is achieved through a high-flux sequencing platform, the genetic polymorphism of chemotherapy medicine and various deviant forms such as point mutation, insertion / deletion and DNA copy number alteration in targeted medicine related gene can be detected at a time in parallel, and therefore all target gene mutations related to targeted chemotherapy treatment are detected at a time. Thus, options are provided for clinical doctors in a real sense, a more suitable treatment scheme can be obtained only through single detection, and treatment cost and time are saved for patients to a larger extent.
Owner:北京元码医学检验实验室有限公司

Somatic copy number alteration obviousness detection method based on two-dimension statistic model

ActiveCN103778350ASpecial data processing applicationsCoefficient of relationshipSomatic cell
The invention provides a somatic copy number alteration obviousness detection method based on a two-dimension statistic model. The somatic copy number alteration obviousness detection method based on the two-dimension statistic model comprises the steps that S1, SCNA data are acquired and pre-processed; S2, the coefficient of relationship between every two adjacent SCNA loca is worked out, and a chromosome is divided into a plurality of SCNA structural units which are independent relatively; S3, the statistic of each SCNA structural unit is worked out, and two-dimension random permutation is conducted on a whole genome; S4, according to different lengths L of the SCNA structural units, null distribution D[L] based on the L is established in a two-dimension space through calculation of the statistic of any SCNA structural unit with the length L in a permutation sample; the statistic of the corresponding SCNA is compared with the D[L], and the statistic of the corresponding SCNA and the D[L] are marked as a value p; if the value p is smaller than a set threshold value, the corresponding SCNA is obvious, and potential cancer exists.
Owner:XIDIAN UNIV

Probe kit for detecting target gene copy-number alteration in t(8;21) AML

ActiveCN103627787AImprove stabilityCombination probes with high signal strengthMicrobiological testing/measurementReady to useWt1 gene
The invention relates to a probe kit for detecting target gene copy-number alteration in t(8;21) AML. The probe kit includes a ready-to-use hybridization solution which comprises an AML1 gene probe, an ETO gene probe, a WT1 gene probe, a P27 gene probe and a C-kit gene probe, wherein the concentrations of all the gene probes are 4 ng / mu L. The probe kit provided by the invention has high combined probe signal intensity and strong stability and can realize qualitative and quantitative detection of changes of 5 target genes at a single cell level at the same time.
Owner:INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Tool for diagnosis and prognosis of mature b-cell neoplasms

InactiveUS20110160079A1Nucleotide librariesMicrobiological testing/measurementMature B-Cell NeoplasmCancer type
The present invention provides a microarray useful as a tool in the diagnosis and / or prognosis of certain types of cancers, particularly mature B-cell neoplasms. The microarray can include a plurality of genomic regions represented thereon, the genomic regions corresponding to regions wherein alterations, such as copy number alterations, at such locations correlate to specific, identifiable cancers, particularly mature B-cell neoplasms. The invention further provides methods of diagnosing and providing prognosis certain types of cancer, particularly mature B-cell neoplasms. The methods can comprise contacting a sample to a microarray according to the invention, allowing any genetic material in the sample to hybridize to the genomic regions on the microarray, analyzing the hybridizations, and correlating the hybridizations to certain cancer types, particularly mature B-cell neoplasms.
Owner:CANCER GENETICS

Methods of detecting somatic and germline variants in impure tumors

A system is provided that considers allele fraction shifts as a function of copy number and clonal heterogeneity. The system leverages differences between allele frequencies to differentiate between somatic and normal variants in impure tumor samples. In solid tumors, stromal cells and infiltrating lymphocytes are typically interspersed among the tumor cells. The normal cell contamination in tumors can be leveraged to differentiate somatic from germline variants. We explicitly model allelic copy number and clonal sample fractions so that we can examine how these factors impact the power to detect somatic variants. The system models the copy number alterations, which can also affect the allele frequencies of both somatic and germline variants. The expected allele frequencies can be calculated. The expected allele frequencies for somatic and germline differ with tumor content for different copy number alterations.
Owner:TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Biopsy-Driven Genomic Signature for Prostate Cancer Prognosis

There is provided herein, systems, devices and methods for determining a risk of recurrence of cancer following a cancer therapy of a patient by determining genomic instability of a tumour. There is further provided systems, devices and methods for categorizing a patient into a prognostic cancer sub-group by using copy number alterations.
Owner:UNIV HEALTH NETWORK +1

Methods for non-invasive assessment of copy number alterations

Technology provided herein relates in part to methods, processes, machines and apparatuses for non-invasive assessment of copy number alterations. In particular, a method is provided for determining presence or absence of a copy number alteration for a test subject. The method includes providing a set of sequence reads. The sequence reads may be obtained from circulating cell free sample nucleic acid from a test sample obtained from the test subject, and the circulating cell free sample nucleic acid may be captured by probe oligonucleotides under hybridization conditions. The method further includes determining a probe coverage quantification of the sequence reads for the probe oligonucleotides and determining the presence or absence of a copy number alteration in the circulating cell free sample nucleic acid based on the probe coverage quantification of the sequence reads for the probe oligonucleotides for the test sample.
Owner:SEQUENOM INC

Copy number alterations that predict metastatic capability of human breast cancer

Disclosed in this specification is a method of defining chromosome regions of prognostic value by summarizing the significance of all SNPs (single nucleotide polymorphism) in a predetermined section of a chromosome to define chromosome regions of prognostic value. Based on the SNPs in specified genes, a more accurate prognosis for breast cancer may be provided.
Owner:VERIDEX LCC

Medulloblastoma genes as targets for diagnosis and therapeutics

Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found that, on average, each tumor had 11 gene alterations, markedly fewer than in common adult cancers. In addition to alterations in the Hedgehog and Wnt pathways, our analysis led to the discovery of genes not previously known to be altered in MBs. Most notably, inactivating mutations of the histone H3K4 trimethylase genes MLL2 or MLL3 were identified in 16% of MB patients. These results demonstrate key differences between the genetic landscapes of adult and childhood cancers, highlight dysregulation of developmental pathways as an important mechanism underlying MBs, and identify a role for a specific type of histone methylation in human tumorigenesis.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1

Use of combined CD274 copy number changes and TMB to predict response to immunotherapies

Provided herein are methods related to detecting cluster of differentiation 274 (CD274) copy number alterations and / or tumor mutational burden (TMB), as well as methods of treatment and uses related thereto. Detection of CD274 copy number alterations and / or TMB can be used to identify individuals having cancer that may benefit from treatment with an immunotherapy.
Owner:FOUNDATION MEDICINE INC

Accurate allele-specific somatic copy number calling from picogram quantities of DNA

The invention relates to a method of determining somatic allele-specific copy number alterations (CNAs) in the genomes of cells in a test-sample from a subject, the method comprising: i) providing an indexed-DNA library of DNA fragments resulting from whole-genome amplification of genomic DNA from cells of the test-sample, ii) providing whole genome sequencing data of reference non-cancer cells from a reference-sample from the subject; and iii) determining somatic allele-specific copy number alterations in the genome(s) of the cells of the test-sample; and associated methods and uses in cancer therapy.
Owner:OXFORD UNIVERSITY INNOVATION LTD

Methods and systems for detecting and removing contamination for copy number alteration calling

Methods and systems for performing iterative contamination detection and segmentation of sequence read data are described. The methods are based on comparing a distribution of minor allele frequencies (MAPs) for a plurality of single nucleotide polymorphisms (SNPs) detected in the sample to an expected distribution of minor allele frequencies for a plurality of selected SNP loci, and adjusting a MAP threshold used to discriminate between aberrant SNPs (SNPs exhibiting a different distribution of MAP values than that expected for the plurality of selected SNPs) and those conforming to the expected distribution of minor allele frequencies for the plurality of selected SNP loci. The methods may be used to estimate the degree of contamination in a sample and to provide segmentation of sequence read data for the sample, and may further comprise building a copy number model that predicts a copy number for one or more gene loci.
Owner:FOUNDATION MEDICINE INC

Methods and systems for automated calling of copy number alterations

Methods and systems for automated calling of copy number alterations (CNAs) are described. The methods and systems utilize sequencing-based coverage ratio data, allele fraction data, segmentation data, and copy number model data for one or more gene loci within one or more subgenomic intervals in a sample from a subject to detect amplifications and deletions of gene loci, and apply a number of thresholds and filters to provide automated calling of CNAs with improved reliability while eliminating the need for process-matched controls and manual curation of the sequencing data.
Owner:FOUNDATION MEDICINE INC

Methods for neoplasia detection from cell free DNA

The disclosure features compositions and methods that are useful for determining the fraction of tumor-derived DNA (tumor fraction; TF) in cell free DNA (cfDNA). The methods involve calculating the fraction of tumor-derived DNA in the cfDNA using a combination of copy number alteration data and fragment length distribution data.
Owner:THE GENERAL HOSPITAL CORP +2

Markers of DNA copy number alteration for improved prognostication in prostate cancer

The invention describes DNA copy number alterations (CNAs), identifiable by technologies such as array-based comparative genomic hybridization (array CGH) or fluorescence in situ hybridization (FISH), that define distinct genetic subtypes of prostate cancer, and are useful for improved prognostication and treatment stratification for patients with prostate cancer.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Method for classifying a cutaneous melanoma patient regarding its risk of developing metastases

The present invention relates to a method ex vivo for classifying a cutaneous melanoma patient, regarding its risk of developing metastases. It also relates to the use of a marker gene which underwent a somatic copy number alteration (SCNA) for classifying a cutaneous melanoma patient regarding its risk of developing metastases. Furthermore, it relates to a method ex vivo for identifying treatment targets in a cutaneous melanoma patient. The invention also relates to a method of selecting a treatment of a cutaneous melanoma patient.
Owner:EBERHARD KARLS UNIV TUBINGEN MEDIZINISCHE FAKULTAT

Methods of determining genomic copy number alterations

Disclosed herein are methods for identifying a stable control locus for use in a fluorescence in situ hybridization (FISH) assay and for determining whether copy number alterations (e.g., amplification) of a target genomic locus (e.g., a gene, e.g., cyclin E1 (CCNE1)) has occurred in a biological sample (e.g., a non-neoplastic sample, preneoplastic lesion, and / or a tumor). In particular, the disclosure provides an expanded repertoire of genomic loci that can serve as a stable control (e.g., a stable control locus) for FISH assays aimed at determining copy number alterations of a target genomic locus.
Owner:REPARE THERAPEUTICS INC

Genotyping CYP2d6

Provided herein are methods and systems for allele typing and variant calling. Genotyping CYP2D6 is complicated by the fact that in some cases one or both of the alleles contain tandem rearrangements and / or copy number alterations. Furthermore, some alleles share 100% identical stretches with homologous regions, such as CYP2D7 and CYP2D8P.
Owner:GUARDANT HEALTH INC

Methods and systems for detecting and removing contamination for copy number alteration calling

Methods and systems for performing iterative contamination detection and segmentation of sequence read data are described. The methods are based on comparing a distribution of minor allele frequencies (MAPs) for a plurality of single nucleotide polymorphisms (SNPs) detected in the sample to an expected distribution of minor allele frequencies for a plurality of selected SNP loci, and adjusting a MAP threshold used to discriminate between aberrant SNPs (SNPs exhibiting a different distribution of MAP values than that expected for the plurality of selected SNPs) and those conforming to the expected distribution of minor allele frequencies for the plurality of selected SNP loci. The methods may be used to estimate the degree of contamination in a sample and to provide segmentation of sequence read data for the sample, and may further comprise building a copy number model that predicts a copy number for one or more gene loci.
Owner:FOUNDATION MEDICINE INC

DNA copy number alterations for predicting treatment response in patients with breast cancer

The present invention refers to the in vitro use of DNA copy number alterations (CNAs) for predicting the response of patients with HR+ / HER2− breast cancer to a treatment comprising targeted therapy, such as CDK4 / 6 inhibitors, and / or endocrine therapy; for the prognosis of patients with HR+ / HER2− breast cancer, for monitoring patients with HR+ / HER2− breast cancer, or for classifying patients with HR+ / HER2− breast cancer into responder or non-responder to a treatment comprising targeted therapy, such as CDK4 / 6 inhibitors, and / or endocrine therapy.
Owner:HOSPITAL CLINIC DE BARCELONA +4

Biopsy-driven genomic signature for prostate cancer prognosis

There is provided herein, systems, devices and methods for determining a risk of recurrence of cancer following a cancer therapy of a patient by determining genomic instability of a tumour. There is further provided systems, devices and methods for categorizing a patient into a prognostic cancer sub-group by using copy number alterations.
Owner:UNIV HEALTH NETWORK +1

Methods and systems for HLA loss determination

This present disclosure relates to systems and methods for detecting HLA alterations (e.g., HLA loss of heterozygosity or HLA copy number alterations) in a sample from a subject. The disclosed methods may comprise, for example, receiving sequence read data derived from a tumor sample and a normal sample from the subject; receiving a subject-specific reference sequence for an HLA region of the subject's genome; determining, based on the sequence read data and the subject-specific reference sequence, a number of unique tumor-derived sequence reads and unique normal-derived sequence reads for each of a first allele and a second allele of an HLA gene; and detecting an HLA alteration for the HLA gene based on a tumor allelic ratio and a normal allelic ratio that are determined based on the number of unique tumor-derived sequence reads and unique normal-derived sequence reads for the first allele and second alleles of the HLA gene.
Owner:GENENTECH INC

Liver cancer prognosis method and kit using a genomic quantitative PCR

The invention relates to a liver cancer prognosis method and a kit using a genomic quantitative PCR, and specifically relates to the liver cancer diagnosis method, a diagnostic kit and a novel cancer-associated gene capable of being used for the liver cancer diagnosis. The liver cancer prognosis method is characterized by including the following steps: (1) a step of using an association rule mining method to find out a mark combination capable of effectively predicting the liver cancer prognosis from chromosome copy number alteration (CNA) of liver cancer exploration; and (2) a step of using a genomic quantitative PCR method to check the alteration and predict the liver cancer prognosis according to the selected chromosome copy number alteration mark. According to the prognosis method, after the CNA performing unitization process and being set with an alteration unit, based on which the liver cancer prognosis associated alteration mark derived from the association rule mining method is determined by the multiple genomic quantitative PCR method, so the liver cancer prognosis can be predicted.
Owner:ザカソリックユニバーシティーオブコリアインダストリーアカデミックコーポレーションファウンデーション

Gene mutations and copy number alterations of EGFR, KRAS and MET

Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1